ReviewHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2023
Hypertension in Pregnancy: A Diagnostic and Therapeutic Overview.
Review in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Differential impacts of pregnancy-induced hypertension and chronic hypertension on maternal and foetal health outcomes: a systematic review of outcomes and risk factors.Archives of gynecology and obstetrics · 2026Pooled it
- Blood pressure-lowering treatment for pregnant women with non-severe hypertension: a systematic review and meta-analysis.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- A plethora of laboratory protocols for vitamin D receptor (VDR) gene variants detection: a systematic review of associations with hypertensive disorders of pregnancy.BMC pregnancy and childbirth · 2025Pooled it
- Review
- Association of the maternal fish and PUFA intake with the risk of hypertensive disorders of pregnancy: a nationwide birth cohort-The Japan Environment and Children's Study (JECS).European journal of nutrition · 2026Article
- Long-term cardiovascular risks in patients with hypertensive disorders of pregnancy treated with nifedipine or labetalol.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Labetalol, Nifedipine, and Methyldopa for the Management of Hypertensive Disorders in Pregnancy in Iran: A Cost-Effectiveness Analysis.Health science reports · 2026Article
- Pregnancy as a Window for Hypertension and Cardiovascular Prevention in Women: A Life-Course Perspective Based on the 2025 ESC Guidelines.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026Review
- Physical Activity and Its Association with Gestational Diabetes Mellitus Among Pregnant Women in Saudi Arabia: A Cross-Sectional Study.Journal of clinical medicine · 2026Article
- RAGE-Mediated Signalling in Gynaecological Disorders: Review of Molecular Mechanisms and Therapeutic Perspectives.Expert reviews in molecular medicine · 2026Review
- Article
- Control of HELLP syndrome and pre-eclampsia with microbiota.Molecular biology reports · 2026Review
- Analysis of Influencing Factors of Fundus Functional Lesions in Patients with Pregnancy-Induced Hypertension and Construction of Prediction Model.International journal of women's health · 2026Article
- Association between Maternal Hypertension and Cleft Lip and Palate: A Mendelian Randomization Study.Current medicinal chemistry · 2026Article
- Divergent Blood Pressure Thresholds in Hypertensive Disorders of Pregnancy: A Narrative Review of Global Guideline Discordance and Clinical Implications.International journal of hypertension · 2026Article
- Drug-induced hyperglycemia in obstetrics: key offending drugs, mechanisms, and practical management.Frontiers in pharmacology · 2026Review
- Efficacy and safety of labetalol vs. Hydralazine in pregnant women with severe hypertension.Pakistan journal of medical sciences · 2026Article
- Comparative evaluation of the quality, reliability, and readability of five large language model responses to frequently asked questions on gestational hypertension.Frontiers in public health · 2026Article
- Current Understanding on Hypertensive Disorders in Pregnancy.International journal of general medicine · 2026Review
- Impact of a case management model on maternal and neonatal outcomes in gestational hypertension: a randomized controlled trial.Frontiers in global women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertensive disorders in pregnancy are associated with increased risk of maternal, fetal, and neonatal morbidity and mortality. It is important to distinguish between pre-existing (chronic) hypertension and gestational hypertension, developing after 20 weeks of gestation and usually resolving within 6 weeks postpartum. There is a consensus that systolic blood pressure ≥ 170 or diastolic blood pressure ≥ 110 mmHg is an emergency and hospitalization is indicated. The selection of the antihypertensive drug and its route of administration depend on the expected time of delivery. The current European guidelines recommend initiating drug treatment in pregnant women with persistent elevation of blood pressure ≥ 150/95 mmHg and at values > 140/90 mmHg in women with gestational hypertension (with or without proteinuria), with pre-existing hypertension with the superimposition of gestational hypertension, and with hypertension with subclinical organ damage or symptoms at any time during pregnancy. Methyldopa, labetalol, and calcium antagonists (the most data are available for nifedipine) are the drugs of choice. The results of the CHIPS and CHAP studies are likely to reduce the threshold for initiating treatment. Women with a history of hypertensive disorders in pregnancy, particularly those with pre-eclampsia, are at high risk of developing cardiovascular disease later in life. Obstetric history should become a part of the cardiovascular risk assessment in women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.